AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. for AMERICAN CANCER SOCIETY CALIFORNIA DIVISION INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, icluding: S. 868 and H.R. 1683, the State Flexibility Act ( MOE). Issues realting to inclusion of palliative care as a bundled service within CMS "value-based purcahsing".
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN KEANE | — |
Budget/Appropriations BUD
Federal buget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC (S.3295); the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health. Legislation includes H. Con. Res. 34, establishing the budget for the US Government for FY 2012; and issues relating to consolidation of categorized cancer prevention programs of the Centers for Disease Control and Prevention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN KEANE | — |
Health Issues HCR
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN KEANE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.